Another anti-TGFβ antibody NIS739 was also studied in a phase I/Ib trial as a single agent or in combination with spartalizumab, an anti-PD-1 antibody (PDR001) in patients with RCC and advanced malignancies. Here, PDCD1 is linked to renal cell carcinoma.